Investors & media
Financial data
Find the latest press releases, financial information, and performance updates.
Transforming rare disease care
We are a global specialty biopharmaceutical company expanding possibilities for people with rare diseases. With 50 years of experience in applying our scientific expertise and unique technologies to research, we continue to develop next-generation treatments and expand our global footprint to transform the lives of patients worldwide.
Newsroom
2026.07.17
Givinostat update script
2026.07.15
Givinostat update material
2026.07.15
JCR Pharmaceuticals announces development plan in Japan for givinostat for duchenne muscular dystrophy
2026.06.23
Partial correction: consolidated financial results for the full year ended March 31, 2026 (FY2025) (Japanese standard)
2026.06.23
Partial correction: consolidated financial results for the full year ended March 31, 2025 (FY2024) (Japanese standard)
Performance data and annual reports
JCR Pharmaceuticals (4552.T)
Tokyo Currency in JPY
511.00
-11.00
(-2.11%)
Last updated 07/17/2026 at TSE market close
Quarterly results
Annual reports
Driven by science and compassion, we tackle some of the most complex challenges in rare disease. Every solution we develop is grounded in insight into the genetic and biological foundations of the conditions we aim to treat.
Contact us
Investors & media